Detail akcie Bio Green Med Solution Inc online

Business Summary: Bio Green Med Solution, Inc., formerly Cyclacel Pharmaceuticals, Inc., is a diversified company engaged in both the fire protection and biopharmaceutical industries. It develops medicines based on cell cycle, epigenetics and mitosis biology. Its Polo-like kinase 1 (PLK1) is a serine/threonine kinase with a central role in cell division and an important regulator of the DNA damage checkpoint. PLK1 overexpression correlates with poor patient prognosis in several tumors, including esophageal, gastric, leukemia, non-small cell lung cancer, ovarian, and squamous cell cancers, as well as MYC-amplified cancers. Plogosertib is a novel, small molecule, selective and potent PLK1 inhibitor. Its Fire Safety division specializes in supplying and trading various protective and fire safety equipment to both domestic and international markets. It provides fire safety products, including fire extinguishers, foam systems, fire-resistant doors, personal protective equipment, and fire safety apparel.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Bio Green Med Solution Inc revenues increased 88% to $81K. Net loss applicable to common stockholders decreased 52% to $3.9M. Revenues reflect Pharmaceuticals segment increase from $14K to $81K. Lower net loss reflects Pharmaceuticals segment loss decrease of 60% to $2.3M. Basic Earnings per Share excluding Extraordinary Items increased from -$554.37 to -$2.93.